Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CDC5L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CDC5L Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for biophysical PPI assays. |
View CDC5L Products |
| Gene Delivery | CDC5L Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and splicing reporter assays. |
View CDC5L Products |
| Benchmark Ab | Anti-CDC5L Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View CDC5L Products |
| Validator | CDC5L siRNA Set For knockdown verification and functional validation in tumor cell lines. |
View CDC5L Products |
| Related Target A | PRP19 Core partner in the PRP19-CDC5L spliceosome complex; critical for PPI disruption screening. |
View PRP19 Products |
| Related Target B | PLK1 Interacts with and phosphorylates CDC5L, regulating mitotic progression and G2/M transition. |
View PLK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening (CDC5L-PRP19) | Sequence-verified, high-purity CDC5L and PRP19 recombinant proteins for robust MST/SPR assays. |
| In vitro Splicing Activity Profiling | Endotoxin-controlled WT proteins ensuring minimal background interference in enzymatic assays. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CDC5L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CDC5L therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular small molecule inhibitors and protein degraders (PROTACs). As first-generation splicing inhibitors reach the clinic, the next wave of R&D is targeting specific protein-protein interactions (PPI) within the spliceosome to avoid systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Institutes, Biotech Startups | Osteosarcoma, Glioma, Prostate Cancer | Biophysical Binding / AlphaLISA (Need high-purity CDC5L and PRP19 proteins) |
| PROTAC / Degrader | Emerging Oncology Biotechs | Hepatocellular Carcinoma, Colorectal Cancer | Ubiquitination & Degradation Kinetics (Need Lentiviral reporter lines) |
| RNAi / ASO | RNA Therapeutics Specialists | Refractory Solid Tumors | Knockdown validation (Need verified siRNA and qPCR controls) |